Amgen receives positive CHMP opinion for use of Vectibix® (panitumumab)
Amgen announced the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion to extend the marketing authorization for Vectibix® (panitumumab) to include combination with FOLFIRI as first-line treatment in adult patients with wild-type mCRC. February 27, 2015